Big Data
- Hongjo Choi (Republic of Korea)Social protection and TB: WHO’s Guidance on social protection for people affected by tuberculosis
- Delia Boccia (World Health Organization)TB-associated economic, social, and psychological sequelae, a model
- Graeme Hoddinott (Australia)Post-TB assessments: who, what, when, and what's next?
- Jerry Zifodya (United States)From Relapse to Reinfection: Navigating the Diagnostic Pathway for Recurrent TB
- Grant Theron (South Africa)Overview of CNS post-TB findings in children
- Carien Bekker (United Kingdom)Advocacy and Policy Engagement
- Dickens Bwana (Tanzania), Bruce Mateware (Malawi)WHO Perspectives on Policy Update at Country-level to Advance Post-TB Case
- Kerri Viney (World Health Organization)What is post-TB lung disease? Insights from study of pathology of post-TB lung
- Threnesan Naidoo (South Africa)What can we learn about PTLD pathogenesis from other respiratory diseases? Lesson from ILD and ARDS
- Sara Auld (United States)Mechanisms of increased post-TB cardiovascular disease
- Andrew Dinardo (United States)Clinical implications of the TB- cardiovascular disease
- Moises Huaman (United States)Epi 101: Goals & Pitfalls
- Ailva O'Reilly (United Kingdom)Updates on HDT clinical trials
- Bob Wallis (United States)Measuring CVS Impact Pre-Damage (non-invasive methods, biomarkers, cross-disciplinary research)
- Vernice Peterson (South Africa)Coagulation in TB
- Jennifer van Heerden (United Kingdom| Panel Discussion: Towards answering the complexities of (left-sided) post-TB cardiovascular damage |
Lung function considerations and reference equations
- Denise Banze (Mozambique)